Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 11;114(2):606–618. doi: 10.1111/cas.15608

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Evaluation of AXL expression in relation to the clinical outcomes of osimertinib treatment according to epidermal growth factor receptor (EGFR) mutation status. (A,B) Kaplan–Meier survival curves for (A) progression‐free survival (PFS) and (B) overall survival OS of EGFR‐mutated non‐small cell lung cancer (NSCLC) patients with exon 19 deletion (19del) and exon 21 L858R point mutation (L858R) mutations receiving osimertinib treatment. (C,D) Kaplan–Meier survival curves for (C) PFS and (D) OS of EGFR‐mutated NSCLC patients receiving osimertinib treatment according to EGFR mutation status and AXL expression levels. CI, confidence interval; HR, hazard ratio; NE, not evaluable